Navigation Links
VIVUS Reports First Quarter 2011 Financial Results
Date:5/2/2011

in the offspring of women who were exposed to topiramate during pregnancy. We have reached agreement, subject to the finalization of the written protocol, with the FDA on the retrospective observational study objectives and design, primary endpoints, and eligibility criteria. The co-primary endpoints will be the relative risk of major congenital malformations and oral cleft in the offspring of women exposed to topiramate during pregnancy as compared to a control group that was not exposed to topiramate. The retrospective observational study, will be called FORTRESS, for Fetal Outcome Retrospective TopiRamate ExpoSure Study. In addition, we discussed with the FDA a potential resubmission of the QNEXA NDA for a limited indication, which would include only men and women of non-child bearing potential. Agreement on the content of such a submission has also been reached, should we choose to pursue a limited indication. The final indication and timing of the resubmission will be dependent upon the results of the retrospective observational study. Our goal is to resubmit the QNEXA NDA in the fourth quarter of 2011. We have confirmed with the FDA that any resubmission will be considered a Class 2 resubmission with a 6-month review goal. The FDA has also indicated that a resubmission would likely be discussed at a second advisory committee meeting.  

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. VIVUS to Present at Four Upcoming Investor Conferences in May
2. VIVUS to Present at the 10th Annual Needham Healthcare Conference
3. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
4. VIVUS to Present at Four Upcoming Investor Conferences
5. VIVUS to Present at Two Upcoming Investor Conferences
6. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
7. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
8. VIVUS to Present at Four Upcoming Healthcare Conferences
9. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
10. VIVUS to Present at the Needham and Company Life Sciences Conference
11. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... for application as catalysts, sensors, drug delivery ... photonics and molecular electronics. Gaining knowledge of ... and chemical properties, has been challenging. Now, ... that high-resolution electron microscopy can be used ... all gold atoms are observed. The results ...
(Date:8/22/2014)... The Global and China Diabetes Drugs Industry is ... of the Diabetes Drug industry in Global and China. ... industry, including definitions, applications and industry chain structure. Global ... with a focus on history, developments, trends and competitive ... and Chinese situation is also offered. , The report ...
(Date:8/22/2014)... 2014 Research and Markets has ... Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, ... their offering. The global molecular biology ... and is expected to grow at a CAGR of ... enzymes, kits, & reagents find applications in a large ...
(Date:8/22/2014)... 22, 2014 Nerium International, the ... in the spotlight again. Nerium will showcase its ... NeriumFirmTM Body Contouring Cream to Hollywood’s elite at ... during the 66th Primetime Emmy® Awards. , Developed ... third-party clinical trials show that NeriumAD night cream ...
Breaking Biology Technology:A breakthrough in imaging gold nanoparticles to atomic resolution by electron microscopy 2Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com 2Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com 3Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3
... ... capabilities for Mass Spectrometry-based biomarker discovery will be demonstrated at the 57th ASMS Conference ... Convention Center. , ... Philadelphia, PA (PRWEB) June 1, 2009 -- Genedata , a leading provider of ...
... , - Results Presented at American Society of Clinical ... Tolerated with Favorable Pharmacokinetics and Prolonged Stable Disease in ... 1 Mersana Therapeutics presented preliminary results of a ... XMT-1001, in a poster session at the 2009 Annual ...
... Webinar on June 9 to discuss the prevalence and prevention ... www.connecttoprotect.com - , , BETHESDA, ... (AGA) Institute and Horizon Therapeutics, Inc. today launched Connect ... gastrointestinal (GI) risks associated with the use of non-steroidal anti-inflammatory ...
Cached Biology Technology:Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities 2Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities 3Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors 2Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors 3AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 2AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 3
(Date:8/22/2014)... August 22, 2014 ... has announced the addition of the  ...  report to their offering.  ... is a technology that helps in ... their physical or behavioral features. It ...
(Date:8/22/2014)... RIVERSIDE, Calif. Thomson Reuters , a leading ... five researchers at the University of California, Riverside in ... brightest minds of our times." , To generate the ... (2002-2012) to identify researchers whose published work has had ... included among some 3,200 individuals who published the greatest ...
(Date:8/22/2014)... Jolla, CA Research presented at the 29th ... being developed by Hera Therapeutics Inc. combats three ... cause 70 percent of all cervical cancer. , ... HTI-1968 blocked the replication of HPV-16, HPV-18 and ... and Thomas Broker, Ph.D., who presented the findings ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... 2009 A St. Louis-based team of plant and ... the developing world today announced the formation of ... involving St. Louis Children,s Hospital, The Donald Danforth ... Medicine. Though they share a commonality of ...
... 2009 - Temperature explains much of why cold-blooded ... longer at higher latitudes than at lower latitudes, according ... of the National Academy of Sciences ( PNAS ... candidate Santiago Salinas, both of Stony Brook University,s School ...
... STILLWATER, Okla. In a first to the ... Sciences and Natural Resources will receive $226,890 in grant ... Oklahoma Water Resources Research Institute. OWRRI and USGS ... encroachment and the water cycle in the tallgrass prairie, ...
Cached Biology News:Researchers team up to provide new hope for childhood hunger 2Researchers team up to provide new hope for childhood hunger 3Researchers team up to provide new hope for childhood hunger 4Warmer environment means shorter lives for cold-blooded animals 2Key OSU water research receives national funding 2
... 2 Oligo Microarray Kit (V2), 22K is useful ... stress response. Each microarray contains content derived from ... for Genomic Research (TIGR) and represents 21,500 genes. ... standard 1 x 3? glass slides each containing ...
... discovery projects require screening through a ... clinically relevant data from normal biologic ... is now available to help better ... data flood inherent to biomarker discovery. ...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,523-9) ... assistance. ID clarifier: reusable vial ...
... Speed Shaker ,Product Information ... is a high quality, general purpose shaker with ... the other models in the line, the Orbit ... control panel. Electronic controls are utilized for setting ...
Biology Products: